Patients who live with obesity, type 2 diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease frequently find themselves moving between separate specialist clinics, receiving recommendations drawn from different clinical guidelines even though their conditions share underlying biological pathways and, in many cases, the same therapies. That disconnect is the central concern raised in a new correspondence published in The Lancet, which argues that internal medicine is uniquely positioned to bridge the gap.
The correspondence responds to a Lancet editorial describing cardiometabolic disease as a growing challenge in clinical practice. The editorial noted that these conditions rarely appear in isolation. A patient with type 2 diabetes may also carry a diagnosis of chronic kidney disease, steatotic liver disease, or established cardiovascular disease, yet each condition is typically managed by a different specialist working from a separate set of recommendations. The result, according to the correspondence, is fragmented care that can leave patients and their physicians navigating overlapping — and sometimes conflicting — guidance.
What makes the fragmentation particularly striking is that these diseases are not biologically separate. Obesity, insulin resistance, lipid disorders, inflammation, and vascular injury are interlocking processes that drive cardiometabolic risk across organ systems. Therapies developed in recent years increasingly target these shared mechanisms, offering benefits that extend beyond a single diagnosis. A drug developed for diabetes, for example, may also reduce cardiovascular events or slow kidney decline. A treatment for obesity may improve liver health. Yet the clinical infrastructure that delivers these therapies often remains organized around individual specialties rather than the patient as a whole.
Internal medicine, the correspondence suggests, is well suited to address this problem. Internists are trained to manage complex, multi-system disease and to coordinate care across subspecialties. They are often the first physicians to see patients with overlapping metabolic and cardiovascular risk factors, and they frequently remain involved as conditions progress. By taking a leading role in cardiometabolic care, internal medicine could help consolidate guideline recommendations, reduce duplication, and ensure that patients receive coherent treatment plans rather than a patchwork of specialist advice.
The correspondence does not propose a specific restructuring of clinical services, but it frames the issue as one that deserves attention from the broader medical community. As cardiometabolic disease becomes more prevalent — driven by rising rates of obesity and aging populations — the pressure on health systems to deliver efficient, coordinated care will only increase. Fragmented pathways not only inconvenience patients but also risk missed opportunities for prevention and early intervention, when therapies may have the greatest long-term impact.
The Lancet editorial and the responding correspondence together highlight a tension in modern medicine: specialization has produced deep expertise and remarkable therapeutic advances, but it can also create boundaries that do not match the biology of chronic disease. Cardiometabolic conditions cross those boundaries routinely. Recognizing that reality, the correspondence argues, may require internists to step forward not merely as coordinators but as leaders in the management of a disease cluster that sits at the intersection of endocrinology, cardiology, nephrology, hepatology, and primary care.
For patients, the practical implications are straightforward. A unified approach could mean fewer conflicting instructions, more streamlined appointments, and treatment decisions that account for the whole person rather than a single organ system. For clinicians, it could mean clearer guidance and a more coherent framework for prescribing therapies that act on shared pathways. For health systems, it could mean better use of resources at a time when chronic disease management consumes a growing share of budgets and clinical capacity.
The correspondence stops short of prescribing a detailed roadmap, but its message is direct: cardiometabolic disease is not a collection of unrelated diagnoses, and it should not be treated as one. Internal medicine, with its broad perspective and its focus on the whole patient, has both the opportunity and the responsibility to help close the gap between how these diseases are understood and how they are managed in practice.
10
